Furthermore, the high expression of folate receptors in ovarian carcinomas shown in this study supports the validity of FOLR1 as drug targets in chemotherapy of ovarian cancer, since FOLR1 expression effectively differentiates ovarian cancer tumors with its coexpression with FOLR3, affecting the serosal cavities of tumors [108]. Here, FOLR3 is linked to ovarian cancer.